ABSTRACT
Importance It is postulated that myocardial injury may be common in Coronavirus Disease (COVID-19) reflected by troponin elevation. The nature, degree and mechanism of myocardial injury in affected patients in the United States are unknown.
Objective To describe the severity and trends of myocardial injury in a large cohort of hospitalized patients with confirmed COVID-19.
Design Retrospective cohort study of data captured between February 27th and April 12th, 2020.
Setting Patients were admitted to one of five hospitals in the Mount Sinai Health System (MSHS) in New York City. Data was collected from the hospitals’ EHR.
Participants We included all patients with confirmed COVID-19 admitted to the aforementioned hospitals during the study period who had at least one troponin-I measured within 24 hours of admission.
Exposure(s) (for observational studies) SARS-CoV-2 infection as confirmed by real-time reverse transcriptase polymerase chain reaction (RT-PCR) assay of nasal and pharyngeal swabs.
Main Outcome(s) and Measure(s) During the study period, 2736 patients met the inclusion criteria. Demographics, medical history, admission labs, and all troponin-I measurements during hospitalization were recorded for each patient. Admission troponin levels were characterized as mildly elevated (between one and three times the upper limit of normal) and elevated (above three times the upper limit of normal).
Results The median age was 66.4 years, with 59.6% men and 40.7% over age 70. In those patients with elevated troponins, cardiovascular disease (CVD) including coronary artery disease, atrial fibrillation, and heart failure, were more prevalent as were conditions of chronic kidney disease, hypertension and diabetes. Inflammatory markers were higher among patients with more substantial troponin elevations as well. Patients who had lower hemoglobin, hypo- or hypertension, or tachycardia generally presented with higher troponins.
Conclusions and Relevance Myocardial injury, manifesting as troponin elevation appears to be common among patients hospitalized with COVID-19 but present at generally low levels. Patients with a history of CVD are more likely to have myocardial injury than patients without CVD or risk factors for CVD. Troponin elevation among patients hospitalized with COVID-19 likely represents non-ischemic or secondary myocardial injury.
Key points
Troponin elevation among patients hospitalized with COVID-19 is common, are at low levels, and are associated with higher risk of mortality
Patients with history of cardiovascular disease followed by risk factors of hypertension and diabetes are more likely to have elevated troponins than patients without cardiovascular disease
Troponin elevation among patients hospitalized with COVID-19 may represent non-ischemic or secondary myocardial injury
Competing Interest Statement
Disclosures/Conflict of Interest: Dr. James Januzzi is a Trustee of the American College of Cardiology, has received grant support from Novartis Pharmaceuticals and Abbott Diagnostics, consulting income from Abbott, Janssen, Novartis, MyoKardia and Roche Diagnostics, and participates in clinical endpoint committees/data safety monitoring boards for Abbott, AbbVie, Amgen, CVRx, Janssen, and Takeda. Dr. Sean Pinney has received consulting fees from Abbott, CareDx, Medtronic and Procyrion.
Funding Statement
This work was Supported by U54 TR001433-05, National Center for Advancing Translational Sciences, National Institutes of Health.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding This work was Supported by U54 TR001433-05, National Center for Advancing Translational Sciences, National Institutes of Health.
Disclosures/Conflict of Interest: Dr. James Januzzi is a Trustee of the American College of Cardiology, has received grant support from Novartis Pharmaceuticals and Abbott Diagnostics, consulting income from Abbott, Janssen, Novartis, MyoKardia and Roche Diagnostics, and participates in clinical endpoint committees/data safety monitoring boards for Abbott, AbbVie, Amgen, CVRx, Janssen, and Takeda.
Dr. Sean Pinney has received consulting fees from Abbott, CareDx, Medtronic and Procyrion.
Dr. Zahi Fayad discloses consulting fees from Alexion and GlaxoSmithKline; Research funding from
Daiichi Sankyo; Amgen; Bristol Myers Squibb; Siemens Healthineers. ZAF receives financial compensation as a board member and advisor to Trained Therapeutix Discovery and owns equity in Trained Therapeutix Discovery as co-founder.
Kipp Johnson has received personal fees from Tempus Labs, Inc
Data Availability
The Mount Sinai Institutional Review Board (IRB) approved this research under a regulatory protocol allowing for analysis of patient-level COVID-19 data.
